Abstract
Key message: Targeting CD‐38‐positive ENKL cells with daratumumab might be a promising new treatment option. Systemic administration of daratumumab may be active against intracerebral manifestations of CD‐38‐positive ENKL. Serial EBV‐monitoring in ENKL is a usefool tool for diagnosis, response assessment and detection of relapse.

This publication has 9 references indexed in Scilit: